Control of Hypertension In Pregnancy Study randomised controlled trial—are the results dependent on the choice of labetalol or methyldopa?

To determine whether the difference in outcomes between ‘less tight’ (target diastolic blood pressure [dBP] of 100 mmHg) versus ‘tight’ control (target dBP of 85 mmHg) in the CHIPS Trial (ISRCTN 71416914, http://pre-empt.cfri.ca/;CHIPS) depended on the choice of labetalol or methyldopa, the two most commonly used antihypertensive agents in CHIPS.

[1]  A. Shennan,et al.  Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. , 2015, Obstetrics and gynecology.

[2]  L. Magee,et al.  Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines , 2014, PloS one.

[3]  D. Somerset.  Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[4]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[5]  D. Krewski,et al.  Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[6]  James M. Roberts,et al.  Hypertension in Pregnancy: Executive Summary , 2013 .

[7]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[8]  S. Hernández-Díaz,et al.  Patterns of Outpatient Antihypertensive Medication Use During Pregnancy in a Medicaid Population , 2012, Hypertension.

[9]  A. Nabhan,et al.  A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy , 2008, Journal of perinatal medicine.

[10]  M. Martel.  Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[11]  J. Singer,et al.  The Control of Hypertension In Pregnancy Study pilot trial , 2007, BJOG : an international journal of obstetrics and gynaecology.

[12]  D. Macdonald,et al.  The prevention of the maternal manifestations of preeclampsia by intensive antihypertensive treatment , 1992, British journal of obstetrics and gynaecology.

[13]  S. Blake,et al.  The prevention of the materal manifestationsofreclampsia by intensive antihypertensive treatment , 1991 .

[14]  S. Oparil,et al.  Less-tight versus tight control of hypertension in pregnancy. , 2015, The New England journal of medicine.

[15]  L. Magee,et al.  Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. , 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[16]  Simon L Bacon,et al.  The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2014, The Canadian journal of cardiology.

[17]  L. Magee,et al.  Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. , 2014, Pregnancy hypertension.